Kamada estimates Brazilian sales of AAT at over $1 million in 2010.
Kamada Ltd. (TASE: KMDA) has obtained approval from Brazil's National Health Surveillance Agency (Anvisa) for its Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema. Kamada estimates Brazilian sales of AAT at over $1 million in 2010.
Anvisa granted the approval after visiting Kamada's plant and reviewing the registration file. The approval was the final step before marketing AAT in Brazil. Kamada will market AAT through a local distributor.
Kamada's share rose 3.3% in morning trading to NIS 28.60, giving a market cap of NIS 631 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 27, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009